Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Healthwise Holdings's earnings before interest and taxes (EBIT) for the
six
months ended in Dec. 2025 was HK$2.24 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$10.54 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
China Healthwise Holdings's annualizedROC % for the quarter that ended in Dec. 2025 was -23.01%.
China Healthwise Holdings's annualizedROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 20.31%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
China Healthwise Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 8.97%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Healthwise Holdings EBIT Competitor Comparison
For the Pharmaceutical Retailers subindustry, China Healthwise Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Healthwise Holdings EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, China Healthwise Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where China Healthwise Holdings's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$10.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Healthwise Holdings (HKSE:00348) has a EBIT of HK$10.54 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Healthwise Holdings.
Is China Healthwise Holdings' EBIT too high?
China Healthwise Holdings' current EBIT is HK$10.54 Mil.
How does China Healthwise Holdings' EBIT compare to competitors?
China Healthwise Holdings' EBIT of HK$10.54 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Healthwise Holdings. China Healthwise Holdings's current EBIT is HK$10.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Healthwise Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Healthwise Holdings (HKSE:00348) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.09 — trading 50% above its estimated fair value. The current EBIT is HK$10.54 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Healthwise Holdings (HKSE:00348), the current EBIT is HK$10.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China Healthwise Holdings Ltd is an investment holding company. It operates in three segments: Chinese health products, Money lending business, and investment in financial instruments. The majority of its revenue comes from trading in Chinese health products, which includes, pharmaceutical products, ginseng, and dried seafood products. The company's geographical segments are Hong Kong and the PRC, of which key revenue is derived from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00348 has been successfully added to your 
